- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03678428
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 and ≤70.
- Diagnosed as colorectal adenocarcinoma by histology.
- Confirmed as liver metastases by medical imaging or pathology.
- MDT determined as unresectable liver metastases, defined as:①more than 5 metastases; ②unable to conduct R0 resection; ③no sufficient residual liver volume after resection; ④none of 3 hepatic vein can be reserved after resection, no sufficient blood supply or bibliary duct can be reserved, none of 2 adjacent liver segment can be reserved. Whenever meets any of the criteria mentioned above would be defined as unresectable liver metastases.
- No previous treatment aiming at treating liver metastases, including chemotherapy, surgery, radiotherapy, transcatheter hepatic arterial chemoembolization(TACE) or target therapy.
- Confirmed by CT, MRI or PET/CT(if necessary) that there is no extrahepatic metastases or only oligos extrahepatic metastases(no more than 2 organs and 5 leisions, maximum diameters of single leision ≤ 1cm).
- Unsuitable for cetuximab treatment(RAS mutation, unable to afford the cost).
- No hematologic dysfunction(Platelets >90×10^9/L; WBC >3×10^9/L; Neutrophil >1.5×109/L).
- Serum bilirubin ≤ 1.5 × ULN; aminotransferase ≤ 5 × ULN.
- No ascites; no coagulation dysfunction; albumin ≥ 30g/L.
- Hepatic function was classified as class A by Child-Pugh classification.
- Serum creatinine < 1 × ULN, or creatinine clearance rate(CCR) > 50ml/min(calculated by Cockcroft-Gault formula).
- ECOG scored as 0-1.
- Life expectancy > 3 months.
- Informed consent.
- Willing and able to receive follow-up until death or trial is finished or trial is terminated.
Exclusion Criteria:
- Presence of extensive extrahepatic metastases(more than 2 organs and 5 leisions, or maximum diameter of single leision > 10 cm).
- Severe arterial embolism or ascites.
- Presence of hemorrhagic tendency or coagulation dysfunction.
- Presentive of hypertensive crisis or hypertensive encephalopathy.
- Severe uncontrolled systemic complications, such as infection or diabetes.
- Severe clinical CVD(cardiovascular disease), such as cerebrovascular accident(within 6 months before recruitment), myocardial infarction(within 6 months before recruitment), uncontrolled hypertension; unstable angina pectoris; congestive heart-failure(NYHA 2-4 grade); arrhythmia that needs medication treatment.
- Previous diagnosed or physical examination showed presence of central nervous system(CNS) disease(i.e. primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastases or stroke).
- Previous history of other malignancy within 5 years(except basal cell carcinoma after radical resection and/or cervical carcinoma in situ).
- Received any medication under research within 28 days before the trial.
- Any residual toxicity of previous chemotherapy(except hair loss), i.e. peripheral neuropathy ≥ NCI CTC v3.0 Grade 2, will be excluded from oxaliplatin-based chemotherapy regimen research pair.
- Allergic to any medication involved in the trial.
- Pregnant and lactating women.
- Patient who does not use or refuses to take any appropriate contraceptive measures (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel or sterilization operation), including women of childbearing age (within 2 years after the last menstrual period) and men who are with possible fertility.
- Unable or unwilling to comply with the research plan.
- The existence of any other disease, dysfunction caused by metastatic lesions, or suspicious disease found on the regular examination, which indicating contraindications to the use of study drugs or may bring high risks of treatment related complications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FUDR/Oxaliplatin HAI plus irinotecan
Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump. then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15. This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump. |
Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1.
Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
|
Active Comparator: FOLFOXIRI
Patients will receive Systemic FOLFOXIRI every 28 days: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15. |
Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
Leucovorin 200mg/m2 IV on Day 1 and 15.
5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate and bilateral 95% confidence interval
Time Frame: Up to 2-4 months
|
defined as complete remission rates and partial remission rates after treatment.
|
Up to 2-4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 resection rates
Time Frame: Up to 2-4 months
|
defined as no macroscopic or microscopic residual tumor
|
Up to 2-4 months
|
Depth of tumor regression(DpR)
Time Frame: Up to 2-4 months
|
defined as the largest depth of tumor regression
|
Up to 2-4 months
|
Progress-free Survival(PFS)
Time Frame: Up to 2-4 months
|
defined as the period from the date of receiving treatment to disease progress caused by any reason.
|
Up to 2-4 months
|
Relapse-free Survival(RFS) of patients with resectable tumor
Time Frame: Up to 2-4 months
|
defined as the period from the date of resection to tumor relapse caused by any reason.
|
Up to 2-4 months
|
Overall Survival(OS)
Time Frame: Up to 2-4 months
|
defined as the period from the date of receiving treatment to death caused by any reason.
|
Up to 2-4 months
|
Adverse events, servere adverse events and surgery-related adverse events rates
Time Frame: Up to 2-4 months
|
defined as the incidence and severity of adverse events related to chemotherapy, HAI and surgery.
|
Up to 2-4 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Oxaliplatin
- Leucovorin
- Irinotecan
- Floxuridine
Other Study ID Numbers
- TRIUMPH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on Irinotecan
-
Shanghai Zhangjiang Biotechnology Limited CompanyShanghai Biomabs Pharmaceutical Co., Ltd.CompletedMetastatic Colorectal Cancer
-
ShengFa SuUnknownSmall-cell Lung CancerChina
-
Nelson YeeIpsenActive, not recruitingLocally Advanced Pancreatic Carcinoma(LAPC)United States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedGlioma | Astrocytoma | OligodendrogliomaUnited States
-
Centre Oscar LambretSFCECompleted
-
Boston Scientific CorporationBiocompatibles UK LtdCompletedMetastatic Colorectal CancerUnited Kingdom, Austria, France
-
Baohui HanNot yet recruitingExtensive-stage Small-cell Lung CancerChina
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Japan Clinical Cancer Research OrganizationTaiho Pharmaceutical Co., Ltd.Completed
-
Dong-A University HospitalPusan National University Yangsan HospitalCompletedGastric CancerKorea, Republic of